Product category:
HTS and combinatorial chemistry equipment
News Release from: Cellomics Europe
Edited by the Laboratorytalk Editorial
Team on 08 November 2001
Investing in high content screening
Cellomics has announced that Serono Pharmaceutical Research has invested in high content screening (HCS) technologies with the acquisition of a Cellomics ArrayScanT HCS system
The ArrayScanT HCS system, a proprietary system developed by Cellomics, performs automated acquisition, analysis, and presentation of information on multiple spatial and temporal events in individual cells The ArrayScanT HCS System was developed to provide reliable insight into the efficacy and toxicity of drug candidates
This article was originally published on Laboratorytalk on 11 Oct 2001 at 8.00am (UK)
Related stories
Automation for cell-based drug discovery
The ArrayScan HCS system from Cellomics is a proprietary drug discovery instrument that performs automated measurement and analysis of spatial and temporal events in cells
Measurement of these complex cellular responses provides researchers with additional knowledge that can be critical to accurately determine which targets to investigate and which lead compounds to pursue.
On the new acquisition, Anthony Nichols, SPRI cellular pharmacology group leader commented "The ArrayScanT HCS System will enable us to increase our efficiency, accuracy and output of cell based biological tests for small molecule and therapeutic protein discovery projects." Colleague Tim Wells, VP for discovery R&D at Serono, added "This system will play an important part of our strategy for finding new therapeutic proteins from the human genome".
Serono has six recombinant products on the market, Gonal-F, Luveris, Ovidrel/Ovitrelle, Rebif, Serostim and Saizen (Rebif and Luveris are not currently approved in the USA).
• Cellomics Europe: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
